Sickle cell disease (SCD) is a major genetic disease that manifests early in life and may lead to significant morbidities. One of the health care services that have been effective in reducing the burden of SCD in developed countries is newborn screening (NBS) followed by pneumococcal vaccines, penicillin prophylaxis, and hydroxyurea treatment. Yet, in sub-Saharan African countries, where about 75% of annual affected babies worldwide are born, NBS programmes are largely unavailable. It is not clear whether this is due to technical challenges associated with setting up such programmes, or significant cultural and social barriers to its acceptance in such settings. Our aim was to ascertain the attitudes to and acceptability of NBS in Nigeria among various socio-demographic groups including health professionals, undergraduate students, parents of children with SCD and SCD patients. Data on socio-demographic characteristics, knowledge of SCD and attitude towards NBS were collected using a semi-structured pre-tested questionnaire from April to July 2014 across 15 health institutions and university campuses in Nigeria. Data were collected from 1,301 respondents across Nigeria. There was good knowledge of SCD as an inherited blood disorder. Although 86% of respondents (n = 1,119) supported NBS, there was a statistically significant relationship between support for NBS and age (p = 003), educational status (p = 000) and religion (p = 000). This study suggests that there is a good acceptability of NBS across Nigeria. The main barriers to its use are likely to be financial and practical, rather than social or cultural.
To evaluate all cases managed with the Minimal Invasive Surfactant Therapy (MIST) and its effect on outcome. Respiratory distress syndrome (RDS), a major cause of morbidity and mortality in preterm...
1 September 2021 in The Journal of Maternal-Fetal & Neonatal Medicine
Newborn respiratory support using Bubble Continuous positive airway pressure (bCPAP) has become acceptable in Nigeria as many centers are increasingly reporting its usefulness. There is increasing ...
25 September 2018 in The Journal of Maternal-Fetal & Neonatal Medicine
Background: Surfactant replacement therapy (SRT) is the standard of care in developed countries. Poor access to surfactant limits its use in low resource settings. The extent of its use and the effect of its regular use on the preterm in such settings is unknown. Objective: This study assessed the extent of exogenous surfactant utilization in Nigerian tertiary care facilities and the benefits of its regular use to the preterm population. Methods: A two-phase cross-sectional study design evaluated the response from a respondent administered structured questionnaire addressed to health care providers from 54 centers and a targeted assessment of the outcome of the regular use of exogenous surfactant in a tertiary care facility from January 2014 to December 2016. Results: SRT was available in 16.7% of 54 units evaluated nationally; three (33.3%) were located in south-south and south-west respectively, 2 (22.2%) in southeast and one (11.1%) in north-central regions of the country. Twenty-two percent of the units were private centers, 77.8% were public tertiary care facilities. Four (44.4%) units provide SRT as the standard of care while five (66.6%) provide the service on request. One thousand one hundred twenty babies were admitted to the audited tertiary facility with 550 (49%) as preterms. Only 2.72% received surfactant replacement therapy. Sixty-six percent of recipients survived whilst 33.3% died. Respiratory support positively enhanced outcome in recipients of surfactant therapy. Conclusion: There is a limited use of surfactant nationally. Its use seemed to have improved survival.
14 April 2018 in International Journal of Pediatrics & Neonatal Care
Objective: To assess the effect of postnatal magnesium sulphate in a large cohort of asphyxiated babies. Methods: Ethical approval for this cross sectional survey of cases of perinatal asphyxia over a 19-month period was obtained. Cases were staged for Hypoxic Ischemic Encephalopathy. They were treated with daily infusion of magnesium sulphate at 250 mg per kilogram per dose daily for three doses. Pre-treatment era perinatal asphyxia, historical controls, 2009 to 2014, were comparison group. Other co-morbidities were also treated. Demographic, antepartum, perinatal antecedents and clinical information were noted. Data were analysed as frequencies, chi square using IBM SPSS Statistics 20. The level of significance, p value was set at